AjayKumarGopalMD

Hematologic Oncology

Professor, Medicine, University of Washington School of Medicine: Member, Fred Hutchinson Cancer Research Center; Clinical Research Director- Hematologic Malignancies- Seattle Cancer Care Alliance

Join to view full profile

Dr. Gopal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gopal's full profile

Already have an account?

Office
Seattle Cancer Care Alliance (UW/FHCRC)
825 Eastlake Avenue East
Seattle, WA 98109
Phone+1 206-606-1000
Is this information wrong?

Summary

Dr. Ajay Gopal is an oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including University of Washington Medical Center and Seattle Cancer Care Alliance. He received his medical degree from Emory University School of Medicine and has been in practice 24 years. He specializes in hematologic oncology and is experienced in hematologic oncology, Hodgkin’s lymphoma, non-Hodgkin’s Lymphoma, CLL, transplant, and cellular therapy.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 1997 - 2000
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Emory University School of MedicineClass of 1993

Certifications & Licensure

WA State Medical License 1997 - 2026
NC State Medical License 1996 - 1998
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Start of enrollment: 2003 Aug 01
Completed
Phase 2
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 1999 Feb 01
Completed
Phase 2
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 1999 Oct 01
Completed
Phase 2
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2005 Jan 01
Completed
Phase 1
A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma Start of enrollment: 2009 Nov 01
Terminated
Phase 2
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Start of enrollment: 2009 Feb 01
Terminated
Phase 1
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Start of enrollment: 2010 Aug 01
Completed
Phase 2
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Start of enrollment: 2011 Nov 16
Terminated
Phase 2
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Start of enrollment: 1999 Sep 01
Terminated
Phase 1
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma Start of enrollment: 2013 Mar 20
Recruiting
Phase 2
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies Start of enrollment: 2013 Oct 09
Completed
Phase 1, Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies Start of enrollment: 2014 Mar 13
Completed
Phase 1, Phase 2
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma Start of enrollment: 2014 Oct 01
Completed
Phase 2
Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2014 Oct 10
Active, not recruiting
Phase 1, Phase 2
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies Start of enrollment: 2017 Feb 08
Terminated
Phase 1, Phase 2
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Start of enrollment: 2017 Apr 24
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell m...
Wang, H., Koob, T., Carter, D., Lieber, A., Fromm, J., Gopal, A.> ;Cancer Biology & Therapy. 2024 Dec 31
Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expression.
Chia-Chen Ho, Yajuan Liu, Yu Wu, Kikkeri Naresh, Ajay K Gopal, Ashley M Eckel> ;Cancer Genetics. 2024 Mar 16
Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study.
Laura Samples, Jenna M Voutsinas MPH, Bita Fakhri, Sirin Khajavian, Stephen E Spurgeon, Deborah M Stephens, Alan P Skarbnik, Anthony R Mato, Catherine Broome, Ajay K G...> ;Blood Advances. 2024 Feb 2
A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.
Michael Durando, Ajay K Gopal, Joseph Tuscano, Daniel Persky> ;The Oncologist. 2024 Apr 4
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
Banerjee, R., Hirayama, A., Gauthier, J., Cassaday, R., Shadman, M., Cowan, A., Till, B., Green, D., Kiem, H., Gopal, A., Maloney, D., Banerjee, R., Poh, C.> ;Blood Advances. 2024 Feb 27
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors.
Johnnie J Orozco, Phuong T Vo, Ted A Gooley, Robyn L Haaf, Sally J Lundberg, D Scott Wilbur, Manuela C Matesan, Darrell R Fisher, Ajay K Gopal, Damian J Green, John M ...> ;Clinical Cancer Research. 2024 Jan 17
Pembrolizumab With R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy, and Safety With Long-Term Follow-Up.
Carrie Ho, Ajay K Gopal, Brian G Till, Mazyar Shadman, Ryan C Lynch, Andrew J Cowan, Qian V Wu, Jenna Voutsinas, Heather A Rasmussen, Katherine Blue, Chaitra S Ujjani,...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 1
2 citations
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Zurko, J. C., Rezvani, A. R., Narendranath Epperla, Ambuj Kumar, Syed A Abutalib, Farrukh T Awan, Yi-Bin Chen, Ajay K Gopal, Jennifer Holter-Chakrabarty, Natasha Kekre...> ;Transplantation and Cellular Therapy. 2023 Sep 1
3 citations
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel, Amitkumar N Mehta, Timothy M Kuzel, Svetomir N Markovic, Olivier Rixe, David L Bajor, Th...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
Grace T Baek, Ivan J Huang, Ajay K Gopal> ;Cancer. 2023 Aug 1
1 citations
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.
Solomon A Graf, Ryan C Lynch, Chaitra S Ujjani, Ted A Gooley, Heather Rasmussen, David G Coffey, Andrew J Cowan, Stephen D Smith, Mazyar Shadman, Edus H Warren, Edward...> ;Blood Advances. 2023 Mar 14
13 citations
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Ryan C Lynch, Chaitra S Ujjani, Christina Poh, Edus H Warren, Stephen D Smith, Mazyar Shadman, Brian Till, Vikram M Raghunathan, Stefan Alig, Ash A Alizadeh, Avanti Gu...> ;Blood. 2023 May 25
A multiplexed assay for quantifying immunomodulatory proteins supports correlative studies in immunotherapy clinical trials.
Jeffrey R Whiteaker, Lei Zhao, Regine M Schoenherr, Dongqing Huang, Rachel A Lundeen, Ulianna Voytovich, Jacob J Kennedy, Richard G Ivey, Chenwei Lin, Oscar D Murillo,...> ;Frontiers in Oncology. 2023 Jan 1
1 citations
Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas.
Ryan C Lynch, Christina Poh, Chaitra S Ujjani, Edus H Warren, Stephen D Smith, Mazyar Shadman, Karolyn Morris, Sydney Lee, Heather Rasmussen, Susan Ottemiller, Megan S...> ;Blood Advances. 2023 Jun 13
Evidence-Based Minireview: When should autologous transplant or cellular therapy be considered for follicular lymphoma?
David A Bond, Ajay K Gopal> ;Hematology. American Society of Hematology. Education Program. 2022 Dec 9
2 citations
Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
Lorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, Lorena Panaite, Erin Mullane, Ryan C Lynch, Chaitra Ujjani, Stephen D Smith, Ajay K Gopal, Brian G Till, Filippo Milano...> ;Journal of Cellular and Molecular Medicine. 2022 Dec 1
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
Lorena Panaite, Qian Vicky Wu, Jenna Voutsinas, Erin Mullane, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Stephen D Smith, Ajay K Gopal, Christina Poh, Lorenzo Iovi...> ;Leukemia & Lymphoma. 2022 Dec 1
3 citations
The impact of histological grade on outcomes in follicular lymphoma: An analysis of patients in the SEER database in the context of evolving disease classification and...
Anisha Naik, Ted Gooley, Keith Loeb, Lorinda Soma, Stephen D Smith, Ajay Gopal, Naresh, K.> ;British Journal of Haematology. 2022 Dec 1
26 citations
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Jordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, Joshua A Hill, Vicky Wu, Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Victor A Chow, Ajay K Gopa...> ;Blood. 2022 Jun 30
3 citations
Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8T-cells despite immune checkpoint signaling.
Adam M Greenbaum, Jonathan R Fromm, Ajay K Gopal, A McGarry Houghton> ;Blood Research. 2022 Jun 30
9 citations
The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
Chaitra Ujjani, Mazyar Shadman, Ryan C Lynch, Brian Tu, Philip A Stevenson, Caitlin Grainger, Haiying Zhu, Joshua A Hill, Meei-Li Huang, Leslie Nielsen, Christina Poh,...> ;British Journal of Haematology. 2022 May 1
264 citations
Diagnosis and Management of Multiple Myeloma: A Review.
Andrew J Cowan, Damian J Green, Mary Kwok, Sarah Lee, David G Coffey, Leona A Holmberg, Sherilyn Tuazon, Ajay K Gopal, Edward N Libby> ;JAMA. 2022 Feb 1
7 citations
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer.
David S Hong, Ajay K Gopal, Alexander N Shoushtari, Sandip P Patel, Aiwu R He, Toshihiko Doi, Suresh S Ramalingam, Amita Patnaik, Shahneen Sandhu, Ying Chen, Craig B D...> ;Frontiers in Immunology. 2022 Jan 1
2 citations
Heterologous SARS-CoV-2 Vaccinations in Patients with B-cell Lymphoid Malignancies.
Chaitra S. Ujjani, Alexander L. Greninger, Mazyar Shadman, Joshua A. Hill, Ryan C. Lynch, Edus H. Warren, Ajay K. Gopal> ;American Journal of Hematology. 2021 Nov 22
2 citations
Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.
Sriram Balasubramanian, Brendan P. Hodkinson, Stephen J. Schuster, Nathan Fowler, Judith Trotman, Georg Hess, Bruce D. Cheson, Michael Schaffer, Steven Sun, Sanjay Des...> ;Cancer Medicine. 2021 Nov 17
Join now to see all

Journal Articles

Translating Anti-CD19 CAR T-cell Therapy into Clinical Practice for relapsed/refractory Diffuse Large B-cell Lymphoma
Mazyar Shadman, Ajay K Gopal, Victor A Chow, Blood

Abstracts/Posters

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib Selects for Cells with Elevated Reactive Oxygen Species and Downregulated Phosphatases
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8+ T-Cells Lacking the Hallmarks of Exhaustion
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study
Ajay K. Gopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Indolent Lymphomas: The Marathon Has a New Course
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
The Alpha Emitter Astatine-211 Targeted to CD38 Can Eradicate Multiple Myeloma in Minimal Residual Disease Models
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell TherapyClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Dr. Ajay Gopal Named Stephen H. Petersdorf Endowed Chair in Cancer Care at UW MedicineJanuary 26th, 2023
DLBCL: PFS but No OS Benefit with Polatuzumab-Vedotin Add-OnDecember 17th, 2021
Ibrutinib Add-on 'Almost Certainly' Saves Lives in DLBCLNovember 4th, 2021
Join now to see all

Grant Support

Radioimmunotherapy For LymphomaNational Cancer Institute2011
Radiolabeled Antibody Therapy Of B-Cell LymphomaNational Cancer Institute2005–2009
Proapoptotic Therapy For B-Cell NON Hodgkin'S LymphomaNational Cancer Institute2006–2007
Optimizing Radioimmunotherapy For NON Hodgkin'S LymphomaNational Cancer Institute2000–2005